Studies factors linked to flare-ups and deaths in adults with bronchiectasis in Hong Kong

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with bronchiectasis (not caused by cystic fibrosis) who are clinically stable. It is a study of factors linked to flare-ups and death.

Age

18 years or older

Sex

All sexes can join.

Disease stage

Bronchiectasis confirmed on a high-resolution CT scan. Stable for at least 4 weeks: no flare-up symptoms and no extra antibiotics needed.

Earlier treatment

No extra (supplemental) antibiotic treatment in the 4 weeks before joining.

Main reasons for not taking part

• History of cystic fibrosis
• History of hypogammaglobulinemia
• History of allergic bronchopulmonary aspergilosis
• Unable to give consent

The registry criteria, word for word

What the trial wants to find out

Bronchiectasis is associated with repeated exacerbations which occurs at rates of 1.5-6.5 per patients per year, and are associated with an increased risk of admission and readmission to hospital, and high health care costs. In a local study carried out more than 10 years ago, idiopathic disease dominates and patients with bronchiectasis are mainly female with high hospitalization and mortality rates; 21.9 cases per 100,000 and 2.7 cases per 100,000 respectively. Moreover, exacerbation characterized by increases in symptoms requiring antibiotic treatment is associated with disease progression and significant mortality. Updated prevalence of this disease with the characteristics of etiology, clinical presentation and outcomes are needed to guide further management plan.